ICU Medical (NASDAQ:ICUI) Issues FY24 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $5.40-5.70 for the period, compared to the consensus EPS estimate of $5.24. ICU Medical also updated its FY 2024 guidance to 5.400-5.700 EPS.

Analysts Set New Price Targets

ICUI has been the subject of several research analyst reports. KeyCorp upped their price objective on shares of ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. StockNews.com downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Tuesday. Jefferies Financial Group began coverage on ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $170.25.

ICU Medical Stock Down 0.1 %

Shares of ICU Medical stock opened at $178.01 on Wednesday. ICU Medical has a one year low of $79.85 and a one year high of $188.53. The company has a market cap of $4.35 billion, a P/E ratio of -60.96 and a beta of 0.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The firm has a fifty day moving average of $175.85 and a two-hundred day moving average of $141.75.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.35. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company had revenue of $580.07 million for the quarter, compared to analysts’ expectations of $574.77 million. On average, analysts forecast that ICU Medical will post 3.81 earnings per share for the current year.

Insiders Place Their Bets

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,502 shares of company stock worth $8,445,976. 6.70% of the stock is owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.